Zydus Lifesciences’ Verapamil Approval Analyzed

Zydus Lifesciences has successfully gained final permission from the U.S. Food and Drug Administration (FDA) for their Verapamil Hydrochloride Extended-Release Tablets. These tablets, available in doses of 120 mg, 180 mg, and 240 mg, are used to manage high blood pressure. Effectively controlling blood pressure can significantly reduce the danger of serious heart issues like strokes and heart attacks.

Key Points

1. FDA approved Zydus’ Verapamil for high blood pressure treatment. 2. Tablets available in 120mg, 180mg, and 240mg dosage forms. 3. Reduces risk of strokes and dangerous heart attacks. 4. Production happens in Baddi, Himachal Pradesh, India. 5. Sales reached $24.5 million in the U.S. (September 2025). 6. This expands Zydus’ portfolio of cardiovascular medications.

These tablets will be manufactured at Zydus Lifesciences’ facility in Baddi, Himachal Pradesh, India. This approval means that doctors and patients in the United States can now access this medication.

According to IQVIA data for the months of September through November 2025, Verapamil Hydrochloride Extended-Release Tablets generated annual sales of approximately $24.5 million within the U.S. market.

This approval is an important step for Zydus Lifesciences, further solidifying its presence in the cardiovascular drug market and offering a valuable treatment option for individuals managing hypertension.

“Effective blood pressure control through medication like Verapamil significantly contributes to long-term heart health.”